Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential effects of fingolimod on B-cell populations in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) - 1 Sept 2014

Nakamura Masakazu, Matsuoka Takako, Chihara Norio, Miyake Sachiko, Sato Wakiro, Araki Manabu, Okamoto Tomoko, Lin Youwei, Ogawa Masafumi, Murata Miho, Aranami Toshimasa, Yamamura Takashi

Abstract excerpt

BACKGROUND: Fingolimod is an oral drug approved for multiple sclerosis (MS) with an ability to trap central memory T cells in secondary lymphoid tissues; however, its variable effectiveness in individual patients indicates the need to evaluate its effects on other lymphoid cells. OBJECTIVE: To clarify the effects of fingolimod on B-cell populations in patients with MS. METHODS: We analysed blood samples from 9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP-ribosyl Cyclase 1
Share to B-Lymphocyte Subsets

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunologic Memory

Share to Immunosuppressive Agents

Share to Ki-67 Antigen

Share to Multiple Sclerosis

Share to Sphingosine

Share to Syndecan-1

Source

Identifiers

PMID: 24526661
DOI: 10.1177/1352458514523496

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential effects of fingolimod on B-cell populations in multiple sclerosis.PMID 24526661Read ↗

Fingolimod alters intrathecal B cell maturation in multiple sclerosis patientsSemantic proximity Read ↗

Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients.Semantic proximity Read ↗

IFNβ-1b treatment leads to changes in the B cell subset and cytokine secretion profile in patients with relapsing-remitting multiple sclerosisSemantic proximity Read ↗

Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions.Semantic proximity Read ↗

CD4 and CD8 lymphocyte subsets in cerebrospinal fluid and peripheral blood from patients with multiple sclerosis, meningitis and normal controls.Semantic proximity Read ↗

Blood B Cell and Regulatory Subset Content in Multiple Sclerosis PatientsSemantic proximity Read ↗

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.Semantic proximity Read ↗

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.Semantic proximity Read ↗

Immune surveillance in multiple sclerosis patients treated with natalizumab.Semantic proximity Read ↗

Deficiency of CD8 <sup>+</sup> effector memory T cells is an early and persistent feature of multiple sclerosisSemantic proximity Read ↗

Anti-CD20 therapy depletes activated myelin-specific CD8 + T cells in multiple sclerosisSemantic proximity Read ↗

Unaltered regulatory B-cell frequency and function in patients with multiple sclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.